GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » Cyclically Adjusted PB Ratio

Anavex Life Sciences (Anavex Life Sciences) Cyclically Adjusted PB Ratio : 3.70 (As of Apr. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Anavex Life Sciences's current share price is $3.44. Anavex Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.93. Anavex Life Sciences's Cyclically Adjusted PB Ratio for today is 3.70.

The historical rank and industry rank for Anavex Life Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

AVXL' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 11.22
Current: 3.69

During the past years, Anavex Life Sciences's highest Cyclically Adjusted PB Ratio was 11.22. The lowest was 0.00. And the median was 0.00.

AVXL's Cyclically Adjusted PB Ratio is ranked worse than
71.76% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs AVXL: 3.69

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Anavex Life Sciences's adjusted book value per share data for the three months ended in Dec. 2023 was $1.652. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.93 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Anavex Life Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Anavex Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Cyclically Adjusted PB Ratio Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 116.31 24.87 50.23 16.38 7.38

Anavex Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.46 11.30 9.82 7.38 10.00

Competitive Comparison of Anavex Life Sciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Anavex Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Cyclically Adjusted PB Ratio falls into.



Anavex Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Anavex Life Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.44/0.93
=3.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Anavex Life Sciences's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.652/129.4194*129.4194
=1.652

Current CPI (Dec. 2023) = 129.4194.

Anavex Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.879 99.695 1.141
201406 0.775 100.560 0.997
201409 0.016 100.428 0.021
201412 0.035 99.070 0.046
201503 0.290 99.621 0.377
201506 0.305 100.684 0.392
201509 0.400 100.392 0.516
201512 0.332 99.792 0.431
201603 0.271 100.470 0.349
201606 0.215 101.688 0.274
201609 0.174 101.861 0.221
201612 0.472 101.863 0.600
201703 0.519 102.862 0.653
201706 0.556 103.349 0.696
201709 0.560 104.136 0.696
201712 0.575 104.011 0.715
201803 0.504 105.290 0.620
201806 0.520 106.317 0.633
201809 0.486 106.507 0.591
201812 0.367 105.998 0.448
201903 0.294 107.251 0.355
201906 0.342 108.070 0.410
201909 0.385 108.329 0.460
201912 0.455 108.420 0.543
202003 0.423 108.902 0.503
202006 0.411 108.767 0.489
202009 0.439 109.815 0.517
202012 0.691 109.897 0.814
202103 1.083 111.754 1.254
202106 2.076 114.631 2.344
202109 1.987 115.734 2.222
202112 1.922 117.630 2.115
202203 1.973 121.301 2.105
202206 1.934 125.017 2.002
202209 1.828 125.227 1.889
202212 1.732 125.222 1.790
202303 1.809 127.348 1.838
202306 1.803 128.729 1.813
202309 1.729 129.860 1.723
202312 1.652 129.419 1.652

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anavex Life Sciences  (NAS:AVXL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Anavex Life Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (Anavex Life Sciences) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Executives
Christopher U Missling director, officer: President, CEO, CFO, Treasurer, other: Secretary 61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos 10 percent owner 14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma director 445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Donhauser Peter D.o. director REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Sandra Boenisch officer: PFO & Treasurer 51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden director PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Steffen Thomas director FALLMERAYER STR. 19, MUNICH 2M 80796
Bernd Metzner director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh director, officer: Executive Director
John Robert Chisholm director 16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry director 1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley director 14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach director, officer: President CEO CFO 4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers director 27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052

Anavex Life Sciences (Anavex Life Sciences) Headlines

From GuruFocus